Board of Directors
John Graham has served on our board since March 2017. John is a seasoned senior executive with extensive experience in building global companies and franchises. John’s three decades of global executive and leadership experience includes 18 years with Aventis, where he held responsibilities in Germany, Mexico, Latin America and the United States. Among other things, while at Aventis, John orchestrated the global strategy and development for the company’s multi-billion dollar diabetes franchise. John played an instrumental role in the development and launch of the blockbuster oral antidiabetic Amaryl, as well as the launch of Lantus, the first long-acting insulin analogue that has transformed diabetes therapy and the world’s leading insulin brand. Since leaving Aventis, John has held senior executive positions at Genzyme Corporation, and Ernst & Young.
John was most recently Chief Executive Officer of the Invida Group, a pan-Asian specialty pharma company, which was acquired by the Menarini Group in 2011. After leaving Menarini in 2015 he joined Torreya Partners, a New York based M&A advisory firm, as a Senior Advisor.
John has a BSc in Biochemistry from Imperial College of Science and Technology, London.
Dr. Robert Fischell has served on our board since 2010. Dr. Fischell is an inventor and serial entrepreneur with over 200 issued U.S. patents, including the first implantable insulin pump (MiniMed, acquired by Medtronic).
Dr. Fischell spent 30 years with the Johns Hopkins University Applied Physics Laboratory, which resulted in 53 patents in both aerospace and biomedical technology. Starting in 1969, Dr. Fischell began the formation of 14 private medical device companies that licensed his patents. These companies include Pacesetter Systems, Inc. (purchased by Siemens and now part of St. Jude Medical, Inc.), IsoStent, Inc. (merged with Cordis Company, a Johnson and Johnson Company), NeuroPace, Inc., eNeura, Inc., Angel Medical Systems, Inc., and Svelte Medical Systems, Inc.
Dr. Fischell’s honors include Inventor of the Year for the USA, election to the National Academy of Engineering and the National Academy of Inventors, the Distinguished Physics Alumnus Award of the University of Maryland, Discover magazine’s annual Technology for Humanity award, and several medals for distinguished accomplishments in science, engineering and innovation. In May 2016 Dr. Fischell received the National Medal for Technology and Innovation from President Obama in recognition of being one of the most distinguished inventors in the USA.
Dr. Fischell received a BSME from Duke University and an MS and Sc.D. from the University of Maryland, and received the honorary degree of Doctor of Humane Letters from the Johns Hopkins University in recognition of his many life-saving inventions. In May 2016 Dr. Fischell received an honorary Doctor of Engineering degree from the Stevens Institute of Technology in honor of his outstanding accomplishments in engineering.
Angela Strand has served on our board since 2016. Ms. Strand is the Founder and Managing Director of Strand Strategy, a healthcare management and consulting firm; a Founder of Nohm, a joint venture between Smith Electric Vehicles and FDG Electric Vehicles Ltd. (HK: 729HK), and the Founder and CEO of Cliffdive Records, an independent record label.
Ms. Strand is a serial entrepreneur with more than 25 years of experience in building disruptive, technology-based products and companies across a range of diverse global industries, including biotech/medtech, consumer health, technology, software and transportation & logistics. From 2011-2015, Ms. Strand served as the Chief Marketing Officer and head of business development and government affairs for Smith Electric Vehicles. She has also served as Vice President of Market Development for Proteus Digital Health, and in various executive roles at Aerogen (acquired by Nektar Therapeutics, NASDAQ:NKTR), Novacept (acquired by Cytyc, NASDAQ: CYTC, now NASDAQ: HOLX) and FemRx (acquired by Johnson & Johnson, NYSE: JNJ). Ms. Strand started her career at IBM, FedEx Express, and Baxter Healthcare.
Ms. Strand is also a named inventor with seven issued patents. Ms. Strand received a BS in communications, magna cum laude and an MBA, Dean’s Fellowship from the University of Tennessee.
Les Seff has served on our board since 2016. Mr. Seff currently serves as President of Matthew B. Management, Inc., which provides consulting services to the financial service industry, and has been an expert in several high profile cases. Additionally, he is currently the Chief Operating Officer of AIMPaaS LLC, a financial software company that provides trading and compliance solutions for asset managers.
Mr. Seff has worked in the financial service industry for over 30 years, most of which occurred in a trading environment where he started and managed NASDAQ and other equity trading departments at wholesale firms, retail/institutional firms, discount brokerage firms, and proprietary trading firms. He ran the NASDAQ Trading Department of Fidelity Investments, a unit that he started at Wagner Stott & Co., and subsequently managed at Fidelity, growing the department to the 12th largest in the country.
Mr. Seff has been an Allied Member of the New York Stock Exchange, and the managing member of his own NASD member firm. Mr. Seff received a BBA, cum laude with high honors from Hofstra University, and an MBA from Bernard Baruch College (City University of New York). In recent years he has guest lectured at NYU, Fordham, and Bernard Baruch graduate schools, and until 2010 had been the host and producer of a local access cable TV show in New York State.
Revan Schwartz, JD has served on our board since 2016. Mr. Schwartz is an attorney and currently maintains a private law practice.
Mr. Schwartz has more than 30 years of experience in corporate and securities law. He held the position of General Counsel for AAA Computer, Hafco International Trading Corporation, Bermil Industries, Viking Credit Corp and The Pride Group.
Most recently Revan was Senior Vice President and General Counsel for Andrew Garrett, Inc., a boutique securities and investment banking firm. While with Andrew Garrett, Mr. Schwartz possessed NASD/FINRA Series 4, 7, 24, 27, 53 and 55 licenses. Mr. Schwartz began his career with the East New York Savings Bank (ENYSB) where he held several administrative and management positions, including a position overseeing a life insurance subsidiary.
Mr. Schwartz received a BS, with a major in accounting and a minor in economics, summa cum laude, from New York Institute of Technology, and a JD, cum laude, from St. John’s University. He is currently a member of the New York and Florida bars.
Michael Hauck has served on our board since May 2017. He is the Executive Director of The Getz Group, a $1 billion privately owned pan-Asian trading company focused on healthcare, industrial products, consumer distribution and retailing.
Mr. Hauck has previously held executive and director level positions at companies including, ERM, Interpharma Investments Ltd., Zuellig Pharma Group, Invida Holdings, Target Worldwide Express, 3i plc, Springboard, and Business Health Group Ltd. Additionally, he has served as CEO of Walsh International for eight years, where he led the company’s IPO and eventual sale to IMS Health.
Through his extensive leadership experience, Mr. Hauck has developed expertise across a wide range of industries and functions, including healthcare distribution services, product launch, and commercialization; pharma, medical device, consumer health, and wellness; data aggregation and data solutions; business development, mergers and acquisitions; and personnel and finance.
Mr. Hauck received an MA in politics, philosophy, and economics from St. Catherine’s College, Oxford University, as well as an MBA in marketing and finance from Cranfield School of Management, one of the oldest and most reputable business schools in the United Kingdom.